한글목차

이 보고서는 미국 바이오시밀러 시장의 미래를 좌우할 주요 개발 동향과 과제에 초점을 맞추어 미국 바이오시밀러 시장과 신흥국 시장 전망에 대해 분석합니다. 아달리무맙의 채택과 스텔라라의 바이오시밀러 출시에 대한 지불 측의 견해를 자세히 분석합니다. 최근 FDA의 호환성 지침이 미치는 영향, 공동 브랜드 바이오시밀러의 역할, 지불자가 가격 결정 및 처방 결정에 사용하는 전략에 대한 인사이트를 얻을 수 있습니다. 또한, 규제 불확실성, 오리지네이터의 전술 등 바이오시밀러 도입의 장벽을 다루며, 이러한 요인들이 시장 동향과 의료비 절감에 미치는 영향에 대한 종합적인 개요를 제공합니다.

보고서 내용

• 지난 1년간 지불자, 의사, 환자들 사이에서 바이오시밀러에 대한 인식이 형성된 사건은?
• 아달리무맙 바이오시밀러의 보험 적용에 대한 지불자의 반응은?
• 스텔라라의 바이오시밀러 출시에 대한 지불자의 견해는?
• 호환성은 포뮬러리의 통합에 어떤 영향을 미치며, 어떤 과제가 남아있다고 생각하는가?
• 미국 시장에서 개인 브랜드 공동 바이오시밀러가 미치는 영향은?
• 지불자는 스위칭 및 약국 수준의 대체와 같은 중요한 문제를 어떻게 보고 있는가?
• 미국 바이오시밀러 시장의 장벽은 무엇이며, 어떻게 극복할 수 있을까?
• 시장의 진화를 촉진하기 위해 바이오시밀러 기업에게 지불자가 어떤 조언을 하고 있는가?

주요 기업

영문목차

Delve into the evolving landscape of the US biosimilars market, focusing on the significant developments and challenges that shape its future. This report provides an in-depth analysis of payer perspectives on the adoption of adalimumab and the anticipated launch of Stelara biosimilars. Gain insights into the impact of recent FDA guidance on interchangeability, the role of private-label co-branded biosimilars and the strategies payers employ to navigate pricing dynamics and formulary decisions. This report also addresses the barriers to biosimilar adoption, such as regulatory uncertainties and originator tactics, offering a comprehensive overview of how these factors influence market trends and healthcare savings.

Key Questions Answered:

• 1. What events have shaped the perception of biosimilars among payers, physicians, and patients in the past year?
• 2. How have payers responded to the coverage of adalimumab biosimilars?
• 3. What are payers' views on the upcoming launch of Stelara biosimilars?
• 4. How has interchangeability influenced formulary inclusions, and what challenges remain?
• 5. What is the impact of private-label co-branded biosimilars on the US market?
• 6. How do payers view key issues like switching and pharmacy-level substitution?
• 7. What barriers remain in the US biosimilars market, and how can they be overcome?
• 8. What advice do payers have for biosimilar companies to drive market evolution?

Key Companies:

Partial List of Participating Experts:

• Payer 1, medical director at a national insurance company that covers over 13 million lives
• Payer 2, chief medical officer at a regional managed care organisation with over 20 years of experience
• Payer 3, pharmacy director at a large national pharmacy benefit manager with 19 years of experience
• Payer 4, medical director with 20 years of experience at a managed care health plan covering 4.5 million lives and specialises in Medicaid business
• Payer 5, chief medical officer and chair of the pharmacy and therapeutics (P&T) committee at a leading managed care organisation with over 25 years of experience
• Payer 6, pharmacy director with 19 years of experience at a leading pharmacy benefit manager
• Payer 7, medical director at a national managed care organisation with over 30 years of experience
• Payer 8, director of pharmacy with over 20 years of experience in managed care, handling a national account with 45 million members, including 2 million Medicaid members

Methodology

Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.